As a result of the pegfilgrastim biosimilars market is very concentrated with just a few massive gamers, gaining an in-depth understanding of the highest opponents and their key methods is essential. A brand new report by The Enterprise Analysis Firm supplies detailed info on the pegfilgrastim biosimilars aggressive panorama. Learn on to study key insights from the report.

What Are Pegfilgrastim Biosimilars?

Pegfilgrastim biosimilars are used for the remedy of febrile neutropenia—a life-threatening complication of most cancers chemotherapy—and to extend the manufacturing of infection-fighting white blood cells following transplantation. Biosimilars are organic merchandise which are similar to a biologic that has already been FDA-approved, generally known as a reference drug. Pegfilgrastim biosimilars are copies of the originating treatment, Amgen’s Neulasta (pegfilgrastim).

The Aggressive Panorama

The high 9 opponents available in the market made up a 100% share of the entire market in 2020. The market focus will be attributed to the excessive boundaries to entry by way of excessive prices related to the analysis and growth of pegfilgrastim biosimilars and the stringent rules arrange by regulatory authorities. Going ahead, the market is predicted to see some fragmentation with the rising variety of new entrants.

Coherus Biosciences Inc. was the most important competitor with 52.75% of the market. Coherus Biosciences’ progress technique goals at increasing its pegfilgrastim biosimilars enterprise by commercialization of its pegfilgrastim biosimilar UDENYCA® in several geographies. When it comes to market share dimension, it was adopted by Sandoz (Novartis), Biocon/Mylan, Intas Prescription drugs Ltd, Mundipharma GmbH, Dr. Reddy’s Laboratories, Pfizer Inc., Emcure Prescription drugs (Gennova Biopharmaceuticals Ltd.), and USV Personal Restricted.

The Influence of COVID-19 on Main Gamers

The COVID-19 disaster has impacted many main gamers within the pegfilgrastim biosimilars market. Biocon Biologics reported that the pandemic had important impacts on its biosimilar enterprise. As a result of delayed regulatory inspection, operational slowdowns and decrease consumption brought on by COVID-19, Biocon’s aspiration of reaching $1 billion in annual biosimilar revenues diminished. The corporate’s pegfilgrastim market volumes within the US have been down by 7% in Q2 of FY 2021. It was tougher for business groups to change prospects to biosimilars and enter new markets.

Nonetheless, the latest commercialization of Fulphila (biosimilar Pegfilgrastim) in Canada and Australia added to the corporate’s oncology portfolio with Trastuzumab in each international locations. Biocon expects gross sales of biosimilar Pegfilgrastim and Trastuzumab to choose up within the US and achieve traction in lots of markets throughout Europe. Throughout FY20, Biocon obtained the US FDA’s approval for enhanced manufacturing capability for 2 key biosimilar merchandise, Trastuzumab and Pegfilgrastim. These approvals will allow Biocon to scale up capability multi-fold and handle the rising market alternatives within the US and different international markets.

Equally, Coherus BioSciences was additionally impacted by the onset of the COVID-19 pandemic. Coherus BioSciences, a US-based biopharmaceutical firm that developed UDENYCA®, pegfilgrastim biosimilar of Neulasta, reported decreased gross sales of UDENYCA®. The corporate confronted issue in sustaining and commercializing using UDENYCA® attributable to components equivalent to healthcare suppliers, payers and sufferers not using or adopting UDENYCA® attributable to assets being strained or in any other case centered on the COVID-19 pandemic, and their gross sales group efficacy in promoting UDENYCA® being restricted attributable to such strained assets and different components equivalent to journey restrictions.

Along with this, main care affected person visits, preventive therapies, diagnostic interventions and nonurgent surgical procedures all displayed a downward development in the course of the pandemic, inflicting monetary hurdles and potential long-term, destructive medical penalties, which negatively affected the pegfilgrastim biosimilars market.

Giant Variety of Strategic Partnerships

Firms within the pegfilgrastim biosimilar market are growing their product innovation by strategic collaborations. To keep up their place within the more and more aggressive market, corporations are creating revolutionary merchandise in addition to sharing expertise and experience with different corporations.

Whereas corporations have lengthy collaborated with one another in addition to with tutorial and analysis establishments on this market by the use of partnerships, in- or out-licensing offers, this development has been growing over latest years. As an illustration, in July 2018, Fulphila, co-developed by Biocon Biologics and Mylan, was the primary biosimilar pegfilgrastim to be permitted by the FDA. In February 2021, Biocon Biologic Ltd. signed a partnership settlement with the Clinton Well being Entry Initiative (CHAI) to broaden their lifesaving most cancers biosimilars in additional than 30 nations in Africa and Asia. The partnership is an important initiative in delivering superior most cancers therapies.

Rising Mergers and Acquisitions

The main target areas for a lot of corporations within the pegfilgrastim biosimilar market has shifted to growing mergers and acquisitions to accumulate extra manufacturing capabilities. Giant prime manufactures are forming joint ventures or shopping for small or midsized corporations to accumulate new capabilities or achieve entry to new markets.

In October 2020, Ligand Prescription drugs introduced its plan to accumulate Pfenex to broaden the product portfolios and capabilities of the corporate for $438 million. The acquisition is predicted to construct Ligand Prescription drugs capabilities and to considerably enhance its market share within the pegfilgrastim biosimilars market. In October 2018, Mundipharma, a UK-based firm engaged in manufacturing, creating, and commercializing high-quality biosimilars for inflammatory illnesses and oncology, acquired Cinfa Biotech.

Participant-adopted methods within the pegfilgrastim biosimilars market general embrace increasing enterprise by commercialization of their merchandise, strengthening enterprise by completely different enlargement methods in several geographies, and getting medicine approvals in several geographies. 

Entry the Full Report

Extra key tendencies, alternatives, and techniques will be present in The Enterprise Analysis Firm’s Pegfilgrastim Biosimilars International Market Report 2021: COVID-19 Progress And Change to 2030, one among a sequence of experiences from The Enterprise Analysis Firm that gives pegfilgrastim biosimilars market overviews, analyzes and forecasts pegfilgrastim biosimilars market dimension, pegfilgrastim biosimilars market gamers, pegfilgrastim biosimilars market segments and geographies, the market’s main opponents’ revenues, profiles and market shares.

About The Enterprise Analysis Firm

The Enterprise Analysis Firm is a market intelligence agency that excels in firm, market, and client analysis. Positioned globally it has specialist consultants in a variety of industries together with manufacturing, healthcare, monetary providers, chemical substances, and know-how. Discover the corporate on LinkedIn, Twitter, Fb, or YouTube for extra.